Luethi, D; Kaeser, PJ; Brandt, SD; Krähenbühl, S; Hoener, MC; Liechti, ME. Pharmacological profile of methylphenidate-based designer drugs. Neuropharmacology, 15 May 2018, 134 (A), 133-140. 987 kB. https://doi.org/10.1016/j.neuropharm.2017.08.020
EMCDDA. New drugs in Europe, 2016, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2017. 489 kB. #39
Luethi, D; Liechti, ME. Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics. Int. J. Neuropsychoph., 1 Oct 2018, 21 (10), 926–931. 254 kB. https://doi.org/10.1093/ijnp/pyy047 #S1 Other Methylmorphenate
Carlier, J; Giorgetti, R; Varì, MR; Pirani, F; Ricci, G; Busardò, FP. Use of cognitive enhancers: methylphenidate and analogs. Eur. Rev. Med. Pharmacol. Sci., 1 Jan 2019, 23 (1), 3–15. 676 kB. https://doi.org/10.26355/eurrev_201901_16741 #Methylmorphenate